Gitanjali Talele
Research Subjects
Research Interests
Gitanjali Talele has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Rajesh Shah
Department of Research, Biosimilia Private Limited, Mumbai, Maharashtra, India
4 shared publications - Jessica Utts
Department of Statistics, University of California, Irvine, California, USA
1 shared publication - Joan A.G. Walter
Samueli Integrative Health Programs, Silver Spring, MD, USA
1 shared publication - John A. Ives
Samueli Institute, Alexandria, VA, USA
1 shared publication - Jyoti Kode
Kode Lab, Tumor Immunology & Immunotherapy Group, Advanced Center for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, Navi Mumbai, India
1 shared publication Kshama Dhobale
Department of Research, Haffkine Institute for Training, Research & Testing, Parel, Mumbai, Maharashtra, India
1 shared publication
Latest Publications
- 30 July 2026
- Published by Georg Thieme Verlag KG in Homœopathic Links
- Vol. 39 (03) , 124-130
Modulation of the Secondary Metabolite Pathways and Enhancement of Curcuma longa Tissue Cultures using Homoeopathic Preparations
Plant tissue culture study of Curcuma longa has shown a remarkable effect of Calendula officinalis 30 on Curcumin production. With this evidence, we planned to study the effect of other potentized homoeopathic medicines on Curcumin production in the tissue culture of Curcuma longa. In addition, we also evaluated their effects on the production of polyphenols in Curcuma longa tissue culture and elucidation of its potential molecular mechanism (metabolic pathways). Tissue culture techniques and plant cells were used to observe the effect of various homoeopathic medicines (Calendula officinalis, Cuprum metallicum, Arnica montana, Nitrous oxide, and Cercosporin in 31C potency) and Jasmonic acid on the production of phenols (Curcumin) under controlled conditions. The yield of Curcumin in fold-change with respect to control cultures was estimated by the HPTLC technique. LC-MS analysis of samples was conducted to study metabolic pathways. Maximum Curcumin content increased (three-fold) in cultures which were induced through 20 µM of Jasmonic acid and potentized Cercosporin 31 C (1:20). Arnica montana, Cuprum metallicum, and Nitrous oxide have given a considerable amount of Curcumin in tissue culture. Secondary metabolites were upregulated in samples treated with Cercosporin. All homoeopathic medicines studied contributed to the enhancement of Curcumin content in tissue cultures of Curcuma longa. This novel study also demonstrates the differential modulation of various metabolic pathways of Curcuma longa brought about by the homoeopathic preparations used.
- 30 July 2026
- Published by Georg Thieme Verlag KG in Homœopathic Links
- Vol. 39 (03) , 124-130
Modulation of the Secondary Metabolite Pathways and Enhancement of Curcuma longa Tissue Cultures using Homoeopathic Preparations
Plant tissue culture study of Curcuma longa has shown a remarkable effect of Calendula officinalis 30 on Curcumin production. With this evidence, we planned to study the effect of other potentized homoeopathic medicines on Curcumin production in the tissue culture of Curcuma longa. In addition, we also evaluated their effects on the production of polyphenols in Curcuma longa tissue culture and elucidation of its potential molecular mechanism (metabolic pathways). Tissue culture techniques and plant cells were used to observe the effect of various homoeopathic medicines (Calendula officinalis, Cuprum metallicum, Arnica montana, Nitrous oxide, and Cercosporin in 31C potency) and Jasmonic acid on the production of phenols (Curcumin) under controlled conditions. The yield of Curcumin in fold-change with respect to control cultures was estimated by the HPTLC technique. LC-MS analysis of samples was conducted to study metabolic pathways. Maximum Curcumin content increased (three-fold) in cultures which were induced through 20 µM of Jasmonic acid and potentized Cercosporin 31 C (1:20). Arnica montana, Cuprum metallicum, and Nitrous oxide have given a considerable amount of Curcumin in tissue culture. Secondary metabolites were upregulated in samples treated with Cercosporin. All homoeopathic medicines studied contributed to the enhancement of Curcumin content in tissue cultures of Curcuma longa. This novel study also demonstrates the differential modulation of various metabolic pathways of Curcuma longa brought about by the homoeopathic preparations used.
- Open Access
- 1 September 2025
- Published by SAGE Publications in Global Advances in Integrative Medicine and Health
- Vol. 14
Protection From SARS-CoV-2 Infection With an Oral Nosode (BiosimCovex): A Randomized, Double-Blind, Placebo-Controlled, Phase III Study
Background and Objectives: This study investigated a potentized, oral homeopathic SARS-CoV-2 nosode (BiosimCovex) for safety, efficacy, and immunogenicity against COVID-19 infection. Methods: A phase III, multicentre, randomised, double-blind, placebo-controlled trial was conducted at 13 sites in India. 2671 unvaccinated, RT-PCR and SARS-CoV-2 antibody-negative participants were randomized 2:1 to receive 6 doses over 3 days of BiosimCovex (1781) or placebo (890). SARS-CoV-2 prevention efficacy was assessed through RT-PCR. Efficacy was defined as 100 x (1-IRR), where IRR is the ratio of positive RT-PCR test rates in the BiosimCovex compared to the placebo group. A two-sided Clopper-Pearson 95% confidence interval was adjusted for surveillance time. Immunogenicity was measured by SARS-CoV-2 antibody conversion at days 15, 30, 45, and 60. Safety was assessed through symptom questionnaires and laboratory studies every 15 days. Illness burden was assessed through symptom diaries. Results: Maximum efficacy occurred at day 45 and was 50.06% overall, 71.88% in individuals aged 18-40 years; and 61.57% in females. By day 45, there were 23 positive RT-PCR cases per group (BiosimCovex 1.3%; placebo 2.6%, P = 0.007). A total of fifty-nine positive RT-PCR cases occurred, with thirty-three (1.86%) in the BiosimCovex and twenty-six (2.94%) in the placebo group, for a relative risk (RR) of 0.63 at the end of the study over 60 days. Antibody conversion increased over time, with 48.4% becoming antibody positive by day 60 in the treatment group compared to 13.4% in the placebo group ( P < 0.001). All 169 (6.33%) mild adverse events resolved without sequelae (6.52% in treatment; 5.96% in placebo). There was a significant reduction in symptom duration ( P = 0.0085) in the treatment group for those who became ill. Conclusions: A potentized oral nosode was safe and appeared to prevent SARS-CoV-2 infection and be immunogenic over 60 days. Effectiveness was highest at day 45 in females and in the 18- to 40-year-old age group.
- 1 September 2025
- Published by SAGE Publications in Global Advances in Integrative Medicine and Health
- Vol. 14
Open AccessProtection From SARS-CoV-2 Infection With an Oral Nosode (BiosimCovex): A Randomized, Double-Blind, Placebo-Controlled, Phase III Study
Background and Objectives: This study investigated a potentized, oral homeopathic SARS-CoV-2 nosode (BiosimCovex) for safety, efficacy, and immunogenicity against COVID-19 infection. Methods: A phase III, multicentre, randomised, double-blind, placebo-controlled trial was conducted at 13 sites in India. 2671 unvaccinated, RT-PCR and SARS-CoV-2 antibody-negative participants were randomized 2:1 to receive 6 doses over 3 days of BiosimCovex (1781) or placebo (890). SARS-CoV-2 prevention efficacy was assessed through RT-PCR. Efficacy was defined as 100 x (1-IRR), where IRR is the ratio of positive RT-PCR test rates in the BiosimCovex compared to the placebo group. A two-sided Clopper-Pearson 95% confidence interval was adjusted for surveillance time. Immunogenicity was measured by SARS-CoV-2 antibody conversion at days 15, 30, 45, and 60. Safety was assessed through symptom questionnaires and laboratory studies every 15 days. Illness burden was assessed through symptom diaries. Results: Maximum efficacy occurred at day 45 and was 50.06% overall, 71.88% in individuals aged 18-40 years; and 61.57% in females. By day 45, there were 23 positive RT-PCR cases per group (BiosimCovex 1.3%; placebo 2.6%, P = 0.007). A total of fifty-nine positive RT-PCR cases occurred, with thirty-three (1.86%) in the BiosimCovex and twenty-six (2.94%) in the placebo group, for a relative risk (RR) of 0.63 at the end of the study over 60 days. Antibody conversion increased over time, with 48.4% becoming antibody positive by day 60 in the treatment group compared to 13.4% in the placebo group ( P < 0.001). All 169 (6.33%) mild adverse events resolved without sequelae (6.52% in treatment; 5.96% in placebo). There was a significant reduction in symptom duration ( P = 0.0085) in the treatment group for those who became ill. Conclusions: A potentized oral nosode was safe and appeared to prevent SARS-CoV-2 infection and be immunogenic over 60 days. Effectiveness was highest at day 45 in females and in the 18- to 40-year-old age group.
- Open Access
- 2 December 2024
- Published by Elsevier in Journal of Ayurveda and Integrative Medicine
- Vol. 15 (6) , 101015
Evaluating anticancer potentials of potentized preparations in an in-vivo xenograft model
- 2 December 2024
- Published by Elsevier in Journal of Ayurveda and Integrative Medicine
- Vol. 15 (6) , 101015
Open AccessEvaluating anticancer potentials of potentized preparations in an in-vivo xenograft model
- 9 June 2021
- Published by Georg Thieme Verlag KG in Homeopathy
- Vol. 110 (04) , 263-270
Preparation and Standardization of Nosodes Sourced from Klebsiella Pneumoniae, Salmonella Typhi, Neisseria Gonorrhoeae and Candida Albicans Strains
Background Homeopathic nosodes prepared from organisms and pathological tissues have shown biological effects, encouraging more research. There is a need to develop some new nosodes systematically and to re-make others that were developed over a century ago. In our program of work on nosodes, the bacterial strains Klebsiella pneumoniae (BAA 2146), Salmonella typhi and Neisseria gonorrhoeae (ATCC 43069), and the single-celled fungus Candida albicans (24433, 26790, and 60193) have been identified for preparation. Materials and Methods The systematic and scientific method of preparation of nosodes includes identification, culture, quantification, characterization, preparation, and standardization. Under laminar flow, a suspension of respective bacterial and fungal cells (20 billion cells/mL) was processed as per the Homoeopathic Pharmacopoeia of India (HPI). Culture tests, sterility tests and molecular testing (polymerase chain reaction) were performed to establish the absence of contamination, live organisms and DNA material. Results K. pneumoniae, S. typhi (single, bivalent, or polyvalent), N. gonorrhoeae, and C. albicans nosodes (single and polyvalent) were sourced and prepared from different strains of respective cultures. The nosode preparations were processed by serial dilution and potentization, normally following the HPI guidelines. Molecular test results showed the absence of live organisms or DNA material; culture and sterility test results demonstrated the safety profile of the potentized nosodes. Conclusion K. pneumoniae, S. typhi, N. gonorrhoeae and C. albicans nosodes were successfully prepared. Their therapeutic potential may now be evaluated.
- 9 June 2021
- Published by Georg Thieme Verlag KG in Homeopathy
- Vol. 110 (04) , 263-270
Preparation and Standardization of Nosodes Sourced from Klebsiella Pneumoniae, Salmonella Typhi, Neisseria Gonorrhoeae and Candida Albicans Strains
Background Homeopathic nosodes prepared from organisms and pathological tissues have shown biological effects, encouraging more research. There is a need to develop some new nosodes systematically and to re-make others that were developed over a century ago. In our program of work on nosodes, the bacterial strains Klebsiella pneumoniae (BAA 2146), Salmonella typhi and Neisseria gonorrhoeae (ATCC 43069), and the single-celled fungus Candida albicans (24433, 26790, and 60193) have been identified for preparation. Materials and Methods The systematic and scientific method of preparation of nosodes includes identification, culture, quantification, characterization, preparation, and standardization. Under laminar flow, a suspension of respective bacterial and fungal cells (20 billion cells/mL) was processed as per the Homoeopathic Pharmacopoeia of India (HPI). Culture tests, sterility tests and molecular testing (polymerase chain reaction) were performed to establish the absence of contamination, live organisms and DNA material. Results K. pneumoniae, S. typhi (single, bivalent, or polyvalent), N. gonorrhoeae, and C. albicans nosodes (single and polyvalent) were sourced and prepared from different strains of respective cultures. The nosode preparations were processed by serial dilution and potentization, normally following the HPI guidelines. Molecular test results showed the absence of live organisms or DNA material; culture and sterility test results demonstrated the safety profile of the potentized nosodes. Conclusion K. pneumoniae, S. typhi, N. gonorrhoeae and C. albicans nosodes were successfully prepared. Their therapeutic potential may now be evaluated.